Preventive oral treatment with resveratrol pro-prodrugs drastically reduce colon inflammation in rodents

Journal of Medicinal Chemistry

Volumn 53, Issue 20, 2010, Pages 7365-7376

  Larrosa, Mar ^a   Tomé Carneiro, Joao ^a   Yáñez Gascón, María J ^a   Alcántara, David ^b   Selma, María V ^a   Beltrán, David ^a   García Conesa, María T ^a   Urbán, Cristina ^a   Lucas, Ricardo ^b   Tomás Barberán, Francisco ^a   Morales, Juan C ^b   Espín, Juan Carlos ^a  

^a Research Group on Quality   (Spain)

^b CSIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTRAN SULFATE; MYELOPEROXIDASE; PROSTAGLANDIN; RESVERATROL; RESVERATROL 3 O (6' O BUTANOYL)BETA DEXTROGLUCOPYRANOSIDE; RESVERATROL 3 O (6' O OCTANOYL)BETA DEXTROGLUCOPYRANOSIDE; UNCLASSIFIED DRUG; ACUTE PHASE PROTEIN; CYTOKINE; GLUCOSIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXIDASE; PRODRUG; PROSTAGLANDIN E2; RESVERATROL-3-O-(6'-O-BUTANOYL)GLUCOPYRANOSIDE; RESVERATROL-3-O-(6'-O-OCTANOYL)GLUCOPYRANOSIDE; STILBENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL METABOLISM; COLITIS; COLON MUCOSA; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DRUG ABSORPTION; DRUG DESIGN; DRUG EFFICACY; DRUG METABOLISM; DRUG SYNTHESIS; ENTERITIS; ENZYME ACTIVITY; GASTROINTESTINAL MUCOSA; GASTROINTESTINAL TRANSIT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; MASS SPECTROMETRY; MOUSE; NONHUMAN; PROSTAGLANDIN SYNTHESIS; RAT; STRUCTURE ACTIVITY RELATION; SYMPTOM; THIN LAYER CHROMATOGRAPHY; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL LINE; CHEMICALLY INDUCED; COLON; DRUG EFFECTS; FECES; HUMAN; INTESTINE ABSORPTION; INTESTINE MUCOSA; METABOLISM; MICROBIOLOGY; ORAL DRUG ADMINISTRATION; PATHOLOGY; STEREOISOMERISM; SYNTHESIS;

ACUTE-PHASE PROTEINS; ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL LINE; COLITIS; COLON; CYTOKINES; DEXTRAN SULFATE; DIARRHEA; DINOPROSTONE; FECES; GASTROINTESTINAL TRANSIT; GLUCOSIDES; HUMANS; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; MICE; MICE, INBRED C57BL; PEROXIDASE; PRODRUGS; STEREOISOMERISM; STILBENES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77958452907     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm1007006     Document Type: Article

References (37)

1. Torres, M. I.; Rios, A. Current view of the immunopathogenesis in inflammatory bowel disease and its implications for therapy World J. Gastroenterol. 2008, 14, 1972-1980
2. Engel, M. A.; Neurath, M. F. New pathophysiological insights and modern treatment of IBD J. Gastroenterol. 2010, 45, 571-583
3. Patel, M.; Shah, T.; Amin, A. Therapeutic opportunities in colon-specific drug-delivery systems Crit. Rev. Ther. Drug Carrier Syst. 2007, 24, 147-202
4. Williamson, G.; Manach, C. Bioavailability and bioefficacy of polyphenols in humans. II. Review of 93 intervention studies Am. J. Clin. Nutr. 2005, 81, 243S-255S
5. Baur, J. A.; Sinclair, D. A. Therapeutic potential or resveratrol: the in vivo evidence Nature Rev. 2006, 5, 493-506
6. Martín, A. R.; Villegas, I.; Sánchez-Hidalgo, M.; de la Lastra, C. A. The effects of resveratrol, a phytoalexin derived from red wines, on chronic inflammation induced in an experimentally induced colitis model Br. J. Pharmacol. 2006, 147, 873-885
7. Larrosa, M.; Yáñez-Gascón, M. J.; González-Sarrías, A.; Selma, V.; Toti, S.; Cerón, J. J.; Tomás-Barberán, F. A.; Dolara, P.; Espín, J. C. Effect of a low dose of dietary resveratrol on colonic microbiota, gene expression, inflammation markers, and tissue damage in a DSS-induced colitis rat model J. Agric. Food Chem. 2009, 57, 2211-2220
8. Singh, U. P.; Singh, N. P.; Singh, B.; Hofseth, L. J.; Price, R. L.; Nagarkatti, M.; Nagarkatti, P. S. Resveratrol (trans -3,5,4′- trihydroxystilbene) induces SIRT1 and down-regulates NF-kB activation to abrogate DSS-induced colitis J. Pharmacol. Exp. Ther. 2009, 332, 829-39
9. Cottart, C. H.; Nivet-Antoine, V.; Laguillier-Morizot, C.; Beaudeux, J. L. Resveratrol bioavailability and toxicity in humans Mol. Nutr. Food Res. 2010, 54, 7-16
10. Zhang, Z.; Yu, B.; Schmidt, R. R. Synthesis of mono- and di- O -β-glucopyranoside conjugates of (E)-resveratrol Synthesis 2006, 8, 1301-1306
11. Schmidt, R. R.; Michel, J.; Roos, M. Glycosylimidate, 12 Direkte Synthese von O-und O -Glycosyl-imidaten Liebigs Ann. Chem. 1984, 1343-1357
12. Melgar, S.; Karlsson, L.; Rehnström, E.; Karlsson, A.; Utkovic, H.; Jansson, L.; Michaëlsson, E. Validation of murine dextran sulfate sodium-induced colitis using four therapeutic agents for human inflammatory bowel disease Int. Immunopharmacol. 2008, 8, 836-844
13. Carceller, E.; Salas, J.; Merlos, M.; Giral, M.; Ferrando, R.; Escamilla, I.; Ramis, J.; García-Rafanell, J.; Forn, J. Novel derivatives as prodrugs of 5-aminosalicylic acid and amino derivatives with potent platelet activating factor antagonist activity J. Med. Chem. 2001, 44, 3001-3013
14. Márquez-Ruiz, J. F.; Radics, G.; Windle, H.; Serra, H. O.; Simplicio, A. L.; Kedziora, K.; Fallon, P. G.; Kelleher, D. P.; Gilmer, J. F. Design, synthesis, and pharmacological effects of a cyclization-activated steroid prodrug for colon targeting in inflammatory bowel disease J. Med. Chem. 2009, 52, 3205-3211
15. Krämer, S. D.; Testa, B. The biochemistry of drug metabolism - an introduction: part 7. Intraindividual factors affecting drug metabolism Chem. Biodiversity 2009, 6, 1477-1660
16. 2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells Blood 2002, 100, 1354-1361
17. Wang, D.; Dubois, R. N. The role of COX-2 in intestinal inflammation and colorectal cancer Oncogene 2010, 29, 781-788
18. Sheibanie, A. F.; Yen, J. H.; Khayrullina, T.; Emig, F.; Zhang, M.; Tuma, R.; Ganea, D The proinflammatory effect of prostaglandin E2 in experimental inflammatory bowel disease is mediated through the IL-23 - IL-27 axis J. Immunol. 2007, 178, 8138-8147
19. Jiang, G. L.; Nieves, A.; Im, W. B.; Old, D. W.; Dinh, D. T.; Wheeler, L. The prevention of colitis by E Prostanoid receptor 4 agonist through the enhancement of epithelium survival and regeneration J. Pharmacol. Exp. Ther. 2007, 320, 883-893
20. Rigas, B.; Goldman, I. S.; Levine, L. Altered eicosaind levels in human colon cancer J. Lab. Clin. Med. 1993, 122, 518-523
21. Popivanova, B. K.; Kitamura, K.; Wu, Y.; Kondo, T.; Kagaya, T.; Kaneko, S.; Oshima, M.; Fujii, C.; Mukaida, N Blocking TNF-α in mice reduces colorectal carcinogenesis associated with chronic colitis J. Clin. Invest. 2008, 118, 560-570
22. Xu, Y.; Hunt, N. H.; Bao, S. The role of granulocyte macrophage colony-stimulating factor in acute intestinal inflammation Cell Res. 2008, 18, 1220-1229
23. Bernasconi, E.; Favre, L.; Maillard, M. H.; Bachmann, D.; Pythoud, C.; Bouzourene, H.; Croze, E.; Velichko, S.; Parkinson, J.; Michetti, P.; Velin, D. Granulocyte-macrophage colony-stimulating factor elicits bone marrow-derived cells that promote efficient colonic mucosal healing Inflamm. Bowel Dis. 2009, 16, 428-441
24. + dendritic cells J. Immunol. 2003, 171, 2797-2803
25. Venkatraman, A.; Ramakrishna, B. S.; Pulimood, A. B.; Murthy, S. Increased permeability in dextrane sulphate colitis in rats: time course of development and effect of butyrate Scand. J. Gastroenterol. 2000, 35, 1053-1059
26. Kiela, P. R.; Laubitz, D.; Larmonier, C. B.; Midura-Kiela, M. T.; Lipko, M. A.; Janikashvili, N.; Bai, A.; Thurston, R.; Ghishan, F. K. Changes in mucosal homeostasis predispose NHE3 knockout mice to increased susceptibility to DSS-induced epithelial injury Gastroenterology 2009, 137, 965-975
27. Tedelind, S.; Westberg, F.; Kjerrulf, M.; Vidal, A. Anti-inflammatory properties of the short-chain fatty acids acetate and propionate: a study with relevance to inflammatory bowel disease World. J. Gastroenterol. 2007, 13, 2826-2832
28. Hoshimoto, A.; Suzuki, Y.; Katsuno, T.; Nakajima, H.; Saito., Y. Caprylic acid and medium-chain triglycerides inhibit IL-8 gene transcription in Caco-2 cells: comparison with the potent histone deacetylase inhibitor trichostatin A Br. J. Pharmacol. 2002, 136, 280-286
29. Di Sabatino, A.; Morera, R.; Ciccocioppo, R.; Cazzola, P.; Gotti, S.; Tinozzi, F. P.; Tinozzi, S.; Corazza, G. R Oral butyrate for mildly to moderately active Crohns disease Aliment. Pharmacol. Ther. 2005, 22, 789-794
30. Zhang, H. Q.; Ding, T. T.; Zhao, J. S.; Yang, X.; Zhang, H. X.; Zhang, J. J.; Cui, Y. L. Therapeutic effects of Clostridium butyricum on experimental colitis induced by oxazolone in rats World J. Gastroenterol. 2009, 21, 1821-1828
31. Reagan-Shaw, S.; Nihal, M.; Ahmad, N. Dose translation from animal to human studies revisited FASEB J. 2008, 22, 659-661
32. Dieleman, L. A.; Peña, A. S.; Meuwissen, S. G.; van Rees, E. P. Role of animal models for the pathogenesis and treatment of inflammatory bowel disease Scand. J. Gastroenterol. 1997, Suppl. 223, 99-104
33. González-Sarrías, A.; Espín, J. C.; Tomás-Barberán, F. A.; García-Conesa, M. T. Gene Expression, Cell Cycle Arrest and MAPK Signalling Regulation in Caco-2 cells Exposed to Ellagic Acid and its Metabolites, Urolithins Mol. Nutr. Food Res. 2009, 53, 686-698
34. Espín, J. C.; González-Barrio, B.; Cerdá, B.; López-Bote, C.; Rey, A. I.; Tomás-Barberán, F. A. The Iberian pig as a model to clarify obscure points in the bioavailability and metabolism of ellagitannins in humans J. Agric. Food Chem. 2007, 55, 10476-85
35. Larrosa, M.; González-Sarrías, A.; Yañéz- Gascón, M. J.; Selma, M. V.; Azorín-Ortuño, M.; Toti, S.; Tomás-Barberán, F. A.; Dolara, P.; Espín, J. C. Anti-inflammatory properties of a pomegranate extract and its metabolite urolithin-A in a colitis rat model and the effect of colon inflammation on the phenolic metabolism J. Nutr. Biochem. 2010, 21, 717-725
36. Araki, Y.; Andoh, A.; Fujiyama, Y.; Bamba, T. Development of dextran sulphate sodium-induced experimental colitis is suppressed in genetically mast cell-deficient Ws/Ws rats Clin. Exp. Immunol. 2000, 119, 264-269
37. Eisen, M. B.; Brown, P. O. DNA arrays for analyses of gene expression Methods Enzymol. 1999, 303, 179-205